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Cationic Supramolecular Hydrogels for Overcoming the
Skin Barrier in Drug Delivery
David Limjn,[a, b] Claire Jim8nez-Newman,[a] Mafalda Rodrigues,[a, b] Ar#ntzazu Gonz#lez-
Campo,[c] David B. Amabilino,[d, e] Ana C. Calpena,[b, f] and Lluı¨sa P8rez-Garc&a*[a, b, g]
1. Introduction
Gels, formed by a network of fibers in a solvent, have a particu-
larity in their rheological behavior: they do not flow even
though typically over 95% of their composition is liquid.[1–4]
Many gels are made out of polymer molecules, and they can
be classified depending on the way the molecules attach to
each other to form the fibers: they can be covalently bonded
throughout the whole system to form a polymer (chemical
gels), or they can be composed of smaller subunits that are at-
tached to each other through weaker chemical forces such as
hydrogen bonds, coulombic forces, and van der Waals interac-
tions, among others (supramolecular gels).[2, 5] The covalent at-
tachment of chemical gels leads to the formation of an irrever-
sible, robust material that can be useful in certain biomedical
applications such as contact lenses;[2,6] however, for drug deliv-
ery or other biomedical applications, supramolecular gels (also
called physical gels) are more suitable because they are softer
and non-permanent.[3, 7–9] The majority of existing gels for cuta-
neous applications are supramolecular gels made out of poly-
meric subunits.[10] There has been recent interest in the devel-
opment of supramolecular hydrogels for different biomedical
purposes, such as vaccine adjuvants, and for the incorporation
of nanoparticles for thermochemotherapy;[11–14] nonetheless,
they are made out of polymeric subunits, and gel formation
needs the presence of either a second substance or an enzy-
matic reaction to take place.
A cationic bis-imidazolium-based amphiphile was used to form
thermoreversible nanostructured supramolecular hydrogels in-
corporating neutral and cationic drugs for the topical treat-
ment of rosacea. The concentration of the gelator and the
type and concentration of the drug incorporated were found
to be factors that strongly influenced the gelling temperature,
gel-formation period, and overall stability and morphology.
The incorporation of brimonidine tartrate resulted in the for-
mation of the most homogeneous material of the three drugs
explored, whereas the incorporation of betamethasone result-
ed in a gel with a completely different morphology comprising
linked particles. NMR spectroscopy studies proved that these
gels kept the drug not only at the interstitial space but also
within the fibers. Due to the design of the gelator, drug release
was up to 10 times faster and retention of the drug within the
skin was up to 20 times more effective than that observed for
commercial products. Experiments in vivo demonstrated the
rapid efficacy of these gels in reducing erythema, especially in
the case of the gel with brimonidine. The lack of coulombic at-
traction between the gelator–host and the guest–drug seemed
particularly important in highly effective release, and the inter-
molecular interactions operating between them were found to
lie at the root of the excellent properties of the materials for
topical delivery and treatment of rosacea.
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In contrast, low-molecular-weight gelators (LMWGs) are
smaller molecules that self-assemble to form fibers, and this
leads to supramolecular gels that are commonly thermoreversi-
ble, more easily degraded than polymeric ones, and therefore
optimum for certain biomedical applications such as drug de-
livery.[2, 5] Examples of supramolecular hydrogels can be found
in the literature, in which the importance of ionic interactions
between the gelator and a host in gel formation/melting was
shown.[15] Interesting examples include supramolecular gels for
which host–guest interactions induce self-assembly only above
a certain temperature and melt below it, as opposed to the
majority of thermoreversible gels.[16] Also, the use of bis-imida-
zolium derivatives as LMWGs has been reported,[7, 8] but gel for-
mation can also need the presence of additional solvents such
as glycerol and octanol or ionic liquids.[17]
Our group reported that bis-imidazolium salts are cationic
surfactants that could interact favorably with anions, including
anionic drugs, and possessed a variety of advantages for bio-
medical applications. For instance, they were shown to form
micelles[18] and to deliver anionic drugs when they are stabiliz-
ing gold nanoparticles.[19,20] These surfactants can also act as
LMWGs and form supramolecular hydrogels for drug deliv-
ery.[7, 8] However, recently, all cases of drugs incorporated into
cationic gels have been anionic, as the electrostatic attraction
between the positively charged surfactant and the negatively
charged drug was thought to be the interaction responsible
for the behavior of the material, and these drugs displayed
slow and sustained release. Nevertheless, an extensive part of
the therapy of dermatological diseases is based on the admin-
istration of non-negatively charged drugs. For instance, rosacea
is a chronic, inflammatory skin disease characterized by erythe-
ma, telangiectasia, and papulopustules.[21,22] Its etiology is not
yet completely known, and pharmaceutical products on the
market commonly contain neutral or cationic drugs that only
act upon the medical symptoms. Brimonidine tartrate
(Figure 1), an a2 adrenergic agonist, is commercialized as the
carbopol-based gel MirvasoS for topical use in the treatment
of rosacea, and it provides vasoconstriction.[10] Also, glucocorti-
coids are potent anti-inflammatory drugs that prevent vasodi-
lation; their indirect mechanism decreases the expression of in-
flammatory cytokines and increases the expression of b2-adre-
nergic receptors.[23] Triamcinolone acetonide (Figure 1), consid-
ered an “intermediate-acting” glucocorticoid because of its
plasma half-life, has potency that is five times higher than that
of cortisol.[24] It is commercially available in combination with
other drugs, for example, as the cream PositonS.[25] Betametha-
sone 17-valerate (Figure 1) is considered a long-acting gluco-
corticoid with a potency that is 25 to 40 times higher than
that of cortisol.[24] It is available as the cream CelecremS,[26,27] as
well as other brands, for topical application in inflammatory
and pruritic dermatoses.
Moreover, there is still a lack of appropriate and fast animal
models of rosacea for testing new products in vivo. The new
formulations developed with already-marketed ingredients can
be tested directly in clinical trials without performing animal
tests (e.g. MirvasoS) ;[10] nevertheless, a significant improvement
in the treatment of a disease might need the exploration of
completely new materials such as these supramolecular hydro-
gels, in which case animal tests must first be performed. Thus,
the development of easy and fast animal models is desired for
progress in rosacea therapy.
Furthermore, ethanol is used in many dermatological prod-
ucts on the market, as it works as a disinfectant and provides
a fresh sensation if applied on skin. Hence, its presence in topi-
cal formulations could counteract the local temperature in-
crease in the inflammatory process occurring in rosacea.
For all these reasons, the ability of compound 1·2Br
(Figure 1) to form gels in the presence of neutral or cationic
drugs that could be used in the treatment of rosacea was ex-
plored by using only water and ethanol as solvents. It was ex-
pected that the chemical interactions between the gelator
host network and the guest drugs, lacking ionic interactions,
would drive the delivery behavior of the hydrogels, for in-
stance, by promoting very fast and effective release, which
would render an excellent material for topical delivery. Here,
brimonidine tartrate, triamcinolone acetonide, and betametha-
sone 17-valerate were incorporated in gels based on 1·2Br.
Optimum conditions for gel formation were found, and the
gels were extensively characterized. The release of drugs from
the gels was studied, and drug-permeation experiments in
human skin were performed to assess the suitability of this
novel material as a possible topical drug-delivery agent.
Finally, a possible rapid animal model of rosacea was also
developed on the basis of measuring the decrease in erythema
after inducing vasodilation, and in vivo experiments were per-
formed by using this new model to assess the efficacy of these
novel supramolecular gels as a topical treatment for this dis-
ease.
2. Results and Discussion
2.1. Supramolecular Gel Formation
To study the gelling ability of 1·2Br, the gelator was dissolved
in ethanol, water was added as an antisolvent, and the mixture
Figure 1. Chemical structures of compound 1·2Br and drugs incorporated in
gels.
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was left to stand without disturbance. The influences of the
proportion of solvent, concentration of the gelator, and tem-
perature were screened as an approach to choose suitable gel-
ling conditions.
The proportion of the solvent had a very strong influence
on gel formation, as ethanol was needed to dissolve gelator
1·2Br completely, whereas water played the role of the antisol-
vent. Gels could be formed with ethanol contents between 35
and 50%, and the latter resulted in the fastest formation
(10 min). The gels were found to be stable for at least
6 months at room temperature. Higher proportions of ethanol
prevented the formation of the matrix due to the high solubili-
ty of 1·2Br in this solvent and only led to partial gels (see Fig-
ure S1 in the Supporting Information).
The concentration of the gelator was also crucial to gel for-
mation and stability. Gels could be formed at room tempera-
ture only if the final concentration of 1·2Br in the gels was
+4 mgmL@1. More dilute samples resulted in the formation of
only partial gels. The gel with a concentration of 5 mgmL@1
was already formed after 10 min. An increase in the gelator
concentration decreased the gelling time; the fastest gelling
time was 2 min, which was observed in the 7.5 and
10 mgmL@1 samples (Figure S2). However, no clear difference
in consistency or macroscopic appearance was observed upon
increasing the concentration above 5 mgmL@1. All formed gels
were stable for at least 6 months at room temperature (below
30 8C). Pictures of the gels with different concentrations of
1·2Br were taken at different times and are shown in Fig-
ure S3.
The temperature was also an important parameter to con-
sider upon forming gels with LMWGs[28] such as 1·2Br. Upon
preparing the mixture and leaving to stand at room tempera-
ture (&24 8C) or at 5 8C, gels were formed in only 10 min. Nev-
ertheless, the gels formed at low temperatures had superna-
tant liquids and appeared to flocculate. At 35 8C, gelation did
not occur, and the sample remained as a solution, as it was
above the gel-melting temperature. However, cooling down to
room temperature resulted in a homogeneous gel. No clear
difference in consistency or macroscopic appearance was ob-
served, except for the slight flocculation observed at 4 8C. A
picture of the gels at different temperatures can be seen in
Figure S4.
The time for complete gelation was influenced by the type
and amount of drug incorporated in the mixture. Brimonidine
tartrate was first dissolved in water and was then added to
a solution of the gelator in ethanol. On the other hand, both
triamcinolone acetonide and betamethasone 17-valerate were
dissolved in ethanol together with the gelator, and water was
added to the solution. In general, the gelling time was not al-
tered in the presence of low amounts of drug relative to the
gels without the drug (10 min), but it increased at higher drug
concentrations. An exception was observed in the case of 1·tri-
amcinolone gels, for which, at all drug concentrations tested,
the gelation was faster (2 min) than in gels without the drug.
The results obtained are displayed in Figure 2 and Table S1. For
all cases, no significant differences in consistency or macro-
scopic appearance were observed.
Unless stated otherwise, the optimum conditions were
chosen as 5 mgmL@1 of 1·2Br with an ethanol/water ratio of
1:1, which allowed both making and storage of the mixture at
room temperature. A drug concentration of 5 mgmL@1 was se-
lected for comparison purposes, as it was higher than that of
the commercially available products, which implied an advant-
age in terms of reaching the therapeutic dose.
2.2. Rheological Measurements
Rheological studies of gel 1·2Br with brimonidine tartrate, tri-
amcinolone acetonide, or betamethasone 17-valerate or with-
out a drug were performed to know their viscoelastic behav-
iors. Amplitude sweep tests were performed at a constant fre-
quency of 1 Hz to determine their resistance to rupture, as
shown by the critical stress value (Table S2). The results
showed that the addition of a drug decreased the critical
stress values, and consequently, the structure could be broken
more easily if anointed. In all cases, if the critical stress was
reached, gels showed abrupt rupture rather than slow rupture.
This showed the suitability of this material for a topical phar-
maceutical form.
Additionally, frequency sweep tests were performed in all
gels to determine their resistance to deformation at different
frequencies, shown by the storage (G’) and loss (G’’) moduli,
upon applying a constant shear stress of t=0.5 Pa to be
within the viscoelastic region. As can be observed (see Fig-
ure S5), despite the drug contained in the gel and the frequen-
cy applied, the storage modulus was higher than the loss mod-
ulus (G’>G’’), with no crossover value (G’=G’’). This elastic pla-
teau permits these gels to be classified as “solid-like” gels.[3, 29]
Other examples of elastic plateau behavior can also be found
in polymeric gels[30–33] and in gels made out of LMWGs.[29] By
comparing the G’ values (see Table S2), 1·triamcinolone did
not significantly change its resistance to deformation relative
to that observed for gel 1·2Br. Instead, the addition of either
brimonidine tartrate or betamethasone 17-valerate produced
gels that were almost four times softer, which is even more
suitable for dermal application.
Figure 2. Influence of type and concentration of drug on gelling time.
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2.3. Drug Incorporation into Gel Fibers
Supramolecular gels formed with isomeric compound 1·2Br
can incorporate anionic drugs not only in the interstitial space
of the gel but also inside the gel fibers.[8] This was thought to
be due to an electrostatic interaction between the positively
charged gelator and the negatively charged drug. However,
neither the mechanism of the assembly leading to gelation nor
that of drug incorporation is yet completely understood. That
is why we challenged gel formation with neutral and cationic
drugs such as triamcinolone acetonide, betamethasone 17-val-
erate, and brimonidine tartrate.
Indeed, gels of 1·2Br can be formed with these neutral and
cationic drugs, and 1H NMR spectroscopy shows that these
supramolecular assemblies incorporate non-negatively charged
drugs inside their fibers. By analyzing the spectra of gels
formed in an NMR tube (see Figures S6–S8), no signals of com-
pound 1·2Br can be observed, and consequently, compound
1·2Br assembles completely to form a gel. Also, 1·2Br can as-
semble in the presence of cationic and neutral drugs and in-
corporate them inside its fibers, not only in the interstitial
space. This indicates that such incorporation is not mainly
driven by an electrostatic attraction. If gel 1·2Br is formed in
the presence of a twofold amount of the drug, the amount of
drug incorporated in the fibers is 58% for brimonidine, 84%
for triamcinolone acetonide, and 65% for betamethasone 17-
valerate. This high drug-incorporation behavior makes this
supramolecular material very interesting as a novel drug-deliv-
ery system, as the material can act as a package for the drug
by protecting and facilitating its permeation through the skin.
The scanning electron microscopy (SEM) images of the gels
studied herein with the incorporated drugs reveal a clear dif-
ference in the structures of the fibers depending on the drug
incorporated. As observed in Figure 3a,b, the xerogel of 1·2Br
alone has long fibers, and most of them are longer than 10 mm
with a width of approximately 100 nm. Small groups of two to
six fibers tend to stick together longitudinally to give a ribbon
appearance, for which fibers can be individually seen. These
groups of “ribbons” can bend and intertwine without any geo-
metrical pattern to give a densely packed structure with re-
duced interstitial areas. According to the rheological studies,
the gels are soft and can also break abruptly if critical stress is
reached. This macroscopic break is indeed due to fracture of
the fibers at the microscopic level if anointed. An example of
how these fibers break can be observed in Figure 3c,d. This
soft and easy-to-break behavior becomes especially important
if thinking about rosacea patients, whose inflamed skin de-
mands a comfortable application.
The addition of a drug to gel 1·2Br results in changes in the
overall microscopic appearance, including the morphology of
the fibers. For instance, gel 1·brimonidine (Figure 3e, f) ap-
pears to have a larger number of fibers stuck longitudinally
than gel 1·2Br, whereas gel 1·triamcinolone (Figure 3g,h) has
reduced interstitial areas due to flocculation induced by the
drug.
In all cases, some drug precipitates to give particles of differ-
ent shapes and sizes. This precipitate corresponds to the drug
dissolved in the space between the gel fibers that precipitates
upon evaporation of the solvent before analysis. In the cases
of 1·brimonidine and 1·triamcinolone, the precipitates are
prismatic crystals, whereas for 1·betamethasone (Figure 3 i, j)
they are a spherical amorphous material. Considering that
upon application on the skin some drug could precipitate,
Figure 3. SEM images of gels a–d) 1·2Br, e, f) 1·brimonidine, g,h) 1·triamci-
nolone, and i, j) 1·betamethasone. Rupture pattern of gels 1·2Br are shown
in panels c and d; the same pattern was observed in all gels with drug.
Scale bars represent 10 mm for the images on the left and 3 mm for the
images on the right.
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a drug in an amorphous material is ideal for topical administra-
tion, because it can be redissolved in the lipids and water of
the skin more easily than crystals.[34,35]
Differential scanning calorimetry was used to observe
energy changes upon gelation of 1·2Br. The strategy consisted
in placing the freshly prepared mixture of compound 1·2Br
with water and ethanol inside the equipment cell above the
melting temperature to prevent gelation. The sample was then
cooled down slowly below the melting temperature to form
a gel inside the equipment while measuring the heat capacity
(Cp) as a function of temperature. Thereby, if the gelation was
an exothermic process, a signal would be observed, and the
total enthalpy could be obtained by calculating the area under
the curve. The results (Figure S9a) clearly show that the gela-
tion of 1·2Br is an exothermic process, and the process is simi-
lar to what occurs in a crystallization event with a total enthal-
py release of 14400 calmol@1. Note that the thermograms are
plotted on an increasing temperature scale, but the experi-
ments were performed by decreasing the temperature, and
this they should be read from right to left. As the cooling
speed is known to be 1 8Cmin@1, the speed of gelation at each
moment can also be determined from the heat-capacity
values; for instance, the onset temperature (Tonset) at 22.1 8C is
the point at which gelation starts, and the maximum value
(Tmax) at 20.2 8C is the point at which gelation occurs faster, re-
leasing 5650 calmol@1min@1. Interestingly, it can be seen that
the signal is not symmetrical in shape, but it has a tail on the
left side at 18.8 8C. Thus, this technique permits observation
that, at this point and down to cooler temperatures, the gel-
ling becomes considerably slower and follows asymptotic be-
havior. The derivative of Cp with respect to temperature (dCp/
dT) (Figure S9a) represents the change in the speed of gela-
tion. From this value, it can be determined that within this in-
terval of temperatures (22.1 to 18.8 8C) the majority of the gel
is formed in only 3.3 min, during which 75% of the total gel-
ling enthalpy (tgel75) is already released, as seen by the area
under the curve. This range of temperatures through which
gelation occurs faster is especially interesting if thinking about
the large-scale production of pharmaceutical formulations, as
fabrication times can be importantly decreased.
To assess the thermoreversibility of the material, after cool-
ing the sample down to 5 8C it was heated up again to 35 8C
to melt the gel. Subsequent gelling cycles were performed,
during which the exothermic signal was also observed but the
Tonset value was shifted to 24 8C in the second cycle with no fur-
ther shifts (Figure S9a). These results prove that this material is
completely thermoreversible, whereas the shift in Tonset sug-
gests that heating the sample up to 35 8C melts the gel but
still leaves some gel nucleation points unmelted; it is these nu-
cleation points that facilitate the start of the subsequent gela-
tion. This is also in accordance with the observations of the en-
thalpy released, which decreases very slightly (3%) from the
first cycle to the second cycle but with no further change. De-
tailed data are given in Table S3.
On the other hand, Figure S9b shows that the volume of
the sample does not influence the gelling temperature (Tonset)
but does influence the gelling speed and, therefore, the gelling
time. Upon decreasing the volume of the sample by 50%, the
gelling time (tgel75) is also reduced by 50% (1.6 min) and reach-
es a maximum gelling speed that is three times higher
(17190 calmol@1min@1) than that of the original sample. This
suggests that a higher surface area between the container and
the mixture facilitates gelation, as adhesion of the liquid to the
material helps supramolecular ordering for the formation of
fibers. Therefore, the lower the volume of the sample, the
higher the surface area per milliliter, and this increases the
speed of gelation and reduces the gelling time. This interesting
behavior can be very useful in industrial production, as the
prepared mixture can be packed directly in single doses if it is
still liquid, which makes the process easier and much faster
and, furthermore, useful from the patient’s point of view, as
the dosage becomes more comfortable.
The same calorimetric studies were performed with gels in-
cluding brimonidine tartrate, triamcinolone acetonide, and be-
tamethasone 17-valerate. Figure S9b shows that the type of
drug can influence the gelling time and temperature. Thus, the
gelling process of gel 1·betamethasone is not different from
that of gel 1·2Br, and the addition of brimonidine tartrate pro-
motes the start of the gelation at a higher Tonset. Gel 1·triamci-
nolone starts to form at the highest Tonset, though the gelling
speed is slower, especially at higher temperatures, and thus,
the time for complete gelling is twice that of 1·2Br (Table S3).
This technique demonstrates that a difference in one single
Celsius degree greatly influences the gelling speed and thus
the gelling time. For this reason, the differences observed be-
tween these experiments and the naked-eye observations
(Figure 2) are related to the room temperature, which varies
between 18 and 28 8C.
2.4. Drug-Release Studies
Drug-release experiments were performed to prove that the
drugs incorporated in the gel could be released from the ma-
terial so they could have therapeutic activity if applied on the
skin and also to demonstrate that this release profile did not
limit permeation of the drugs into human skin. The experimen-
tal conditions were adjusted to simulate those in the skin-per-
meation experiments, including the use of Franz cells and
matching the stirring speed and temperature (32 8C is the
normal temperature of the skin). The solvent in the receptor
chamber was always chosen to comply with SINK conditions
to discard the possibility that low solubility would compromise
the results.[36]
In all cases, the drugs could be released from the gel follow-
ing a one-phase exponential association model. Two commer-
cial products were tested for comparison purposes: PositonS,
containing triamcinolone acetonide, and CelecremS, containing
betamethasone 17-valerate. These formulations also followed
the same model. The release profiles are plotted in Figure 4a,
and the equation parameters of all the gels studied are avail-
able (see Table S4).
According to the results, our carrier material permitted
a high level of drug release and did not limit permeation of
the drug into human skin. Gels 1·triamcinolone and 1·beta-
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methasone presented both the highest amount of drug re-
leased and the highest speed of release. Moreover, gels de-
rived from 1·2Br released up to three times more triamcino-
lone or betamethasone than commercial products. Also, the
speed of release of these drugs was ten times faster if they
were incorporated in gel 1·2Br. These results show a promising
improvement in the dermal bioavailability of such drugs if they
are formulated by using this novel material.
2.5. Skin-Permeation Studies
Gels were prepared by incorporating brimonidine tartrate, tri-
amcinolone acetonide, or betamethasone 17-valerate at a drug
concentration of 5 mgmL@1, and permeation studies were per-
formed in the same Franz cells as those used for the drug-re-
lease studies. Available marketed formulations containing bri-
monidine tartrate (MirvasoS), triamcinolone acetonide (Posi-
tonS), or betamethasone 17-valerate (CelecremS) were also
studied for comparison purposes. Moreover, to assess the influ-
ence of the gel material itself and to discard other factors such
as a different concentration of the drug, brimonidine tartrate
was taken as a model and was also incorporated into the gel
of 1·2Br at the same concentration as the commercial product
MirvasoS (3.3 mgmL@1).
As observed in Figure 4b and Table S8 [J values] , the gel
promoted permeation of the drug at a rate up to four times
faster than the marketed products, as observed in 1·triamcino-
lone and 1·betamethasone. Gel 1·brimonidine, in contrast,
Figure 4. a) Drug released [%] from gel based on 1·2Br incorporating brimonidine tartrate (left), triamcinolone acetonide (center), or betamethasone 17-valer-
ate (right). Commercially available formulations containing either triamcinolone acetonide (PositonS) or betamethasone 17-valerate (CelecremS) were studied
for comparison purposes. All values represent the mean of three replicas, and error bars represent one standard deviation. b) Skin permeation of drugs from
a gel based on 1·2Br or commercial formulations. Gel 1·brimonidine and MirvasoS both contain brimonidine tartrate (left), 1·triamcinolone and PositonS
both contain triamcinolone acetonide (center), and 1·betamethasone and CelecremS both contain betamethasone 17-valerate (right). Values represent the
means, and error bars represent one standard deviation. c) Amount of drug retained within the skin per gram and square centimeter after application either
in gel from 1·2Br or in commercial formulations [brimonidine tartrate (left), triamcinolone acetonide (center), and betamethasone 17-valerate (right)] . Differ-
ences with statistical significance: *p<0.05, **p<0.01.
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showed slightly slower permeation than MirvasoS if loaded at
the same concentration; nonetheless, if loaded at a concentra-
tion of 5 mgmL@1, the flux became almost two times higher.
Also, the abscissa intercept in the plots shows the lag time
(tlag), which represents the time it takes for the drug to cross
the epidermis completely and to cross part of the dermis.
These results show that gel 1·2Br promotes the entry of the
drugthrough the skin four times more rapidly than the com-
mercial formulations, which implies faster action. An exception
is the gel 1·brimonidine, since brimonidine tartrate takes
a few less hours if applied in MirvasoS ; nonetheless, the higher
flux values of gel 1·brimonidine provide more drug than Mir-
vasoS 25 h after the initial application, at which time better ef-
ficacy can be expected (see the Supporting Information, bri-
monidine tartrate flux vs. lag time). However, in the case of ro-
sacea, the lag time becomes a less-important parameter in
considering that the chronic nature of the disease implies re-
peated administration of the dose.
In addition, Figure 4c shows the total amount of drug that
can be retained inside the skin after topical application. It is
very interesting that in all cases the gel significantly promotes
retention of the drug, as also seen in Table S8 (As corr.), and rel-
ative to the commercial formulations, the gel provides 2 times
more drug in the case of betamethasone, 3 times more drug
in the case of brimonidine, and up to 20 times more drug in
the case of triamcinolone. The observed permeation flux
values of triamcinolone are lower than those of bethameta-
sone, and this is related to its high retention inside the skin. In
all of the cases, the ability of the gel to promote this retention
is highly beneficial for treatment of rosacea, as the therapeutic
targets of these drugs are located at the dermis and, in the
case of the glucocorticoids, also at the epidermis. Therefore, as
the skin dermatomed includes both the epidermis and part of
the dermis, high retention of the drug implies that more drug
is available at the pharmacological target and, thus, higher effi-
cacy. Furthermore, the skin can also act as a reservoir for the
retained drug, which can continuously be redissolved and per-
meated to provide sustained pharmacological activity and to
permit an increase in the dosing intervals. For this reason, the
use of gels based on 1·2Br in the treatment of rosacea could
also help the common problem of missed doses to be over-
come.[37,38]
2.6. Pharmacological Efficacy In Vivo
The lack of sufficient knowledge in the etiology of rosacea
may be the reason why there are not enough animal models
for this disease. A few examples of possible animal models are
based on neovascularization, vasodilation, and inflammation
upon injection of either the cathelicidin peptide or the enzyme
Kallikrein-5 that produces it ; however, such models can last up
to 4 weeks.[21,39] Thereby, pharmacological efficacy studies for
the treatment of rosacea have always been a challenge. Hence,
it would be of great interest for research on rosacea to devel-
op new fast animal models of the disease.
Therefore, as two of the most important signs of rosacea are
erythema and telangiectasia,[22,40] a model of the disease was
developed in rabbits. For instance, upon application of m-
xylene in the dorsal side of the rabbit ears, severe vasodilation
was observed, especially at the capillary vessels, which also led
to erythema. Both conditions are visible to the naked eye and
last for at least 15 min. Moreover, to obtain quantitative and
precise results, the decrease in erythema was evaluated by
measuring the skin color by using a skin colorimetric probe
that can detect much smaller differences in color than the
naked eye. Hence, this model was used to assess the pharma-
cological efficacy of gels 1·brimonidine, MirvasoS, 1·triamcino-
lone, and 1·betamethasone in the topical treatment of the
disease by inducing vasodilation and by applying the gel while
measuring the skin color with time. Pictures of rabbit ears
treated with 1·brimonidine are shown in Figure 5, and those
from the rest of the treatments as well as the skin color meas-
urements in RGB code can be found in the Supporting Infor-
mation (Figures S12–S14, Tables S9 and S10).
The evolution of erythema can be seen by reproducing the
skin color as a sequence through the different steps: basal
color; induction of vasodilation; and 5, 10, and 15 min after
Figure 5. Pictures showing the evolution of erythema at different times after
treatment with 1·brimonidine. Treatment was applied on the dorsal side of
the rabbit’s right ear, whereas the left ear was not treated as a control.
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treatment with either gel (right ear) or without applying any
treatment (left ear) (see Figure S11). The results show that the
application of m-xylene leads to acute erythema, which ap-
pears immediately and slightly diminishes after 5 min (left ear) ;
however, there is no evolution afterwards, and the color of the
skin does not return to the basal value. On the other hand, by
applying a treatment, the erythema decreases even more
quickly to give a lighter color. Gel 1·brimonidine already de-
creases the erythema from minute 5 and keeps decreasing it
until minute 15. In contrast, MirvasoS shows a clear reduction
only at minute 10, which does not evolve. The difference in ef-
ficacy between these two treatments can also be observed at
the vasoconstrictive level, as gel 1·brimonidine provides clear
vasoconstriction of the capillary vessels (Figure 5 and Fig-
ure S12). In contrast, the application of 1·triamcinolone or
1·betamethasone as treatment apparently does not reduce er-
ythema after 15 min, as the color of the skin remains similar to
that of the control.
To obtain a quantitative comparison between treatments,
the colors must be transformed into single numerical values.
This cannot be done directly for the nature of the color codes;
in this case, colors are given in the RGB code, which is a triple-
number value. The transformation into single numerical values
can only be done indirectly by calculating the differences be-
tween the colors. For instance, the triple code (RGB) is treated
as xyz Cartesian coordinates in a 3D Euclidean space; thus,
a single color is treated as a point and plotted in the xyz scat-
ter chart. Consequently, the difference between two colors is
obtained by measuring the linear distance between the two
respective points. This procedure was used to calculate the dif-
ference between the basal color and the color at each stage
(vasodilation; 5, 10, and 15 min from treatment). The difference
between the basal color and the vasodilation color (vasodila-
tion difference) was considered 100% erythema. Therefore, rel-
ative erythema [%] values were calculated with respect to the
vasodilation difference.
Figure 6 clearly shows the evolution of erythema either with
or without the application of treatment, and it is expressed as
relative erythema. This plot confirms that erythema can de-
crease within 5 min without the application of a treatment
(controls). However, this decrease is partial, as the erythema
values do not return to the basal state (0%); instead, the ma-
jority of the time the values remain around 50%. In contrast,
the application of a treatment can reduce the erythema
beyond the control value, and such a reduction can appear
sooner or later (lag time) depending on the drug it contains.
For instance, 1·brimonidine had the fastest response, and it
significantly reduced erythema only 5 min after application.
Moreover, at the 10 min mark, the redness decreased even
below the basal value and down to @107% after 15 min; both
values are significantly lower than the control (p<0.001). As
opposed to 1·brimonidine, treatment with MirvasoS showed
a lag time of 10 min and provided a relative erythema of 15%
with no significant evolution afterwards. Statistical analysis did
not show MirvasoS to be significantly more effective than its
control ; however, the median relative erythema values were
lower. Upon comparing 1·brimonidine with MirvasoS, no stat-
istically significant differences were obtained, though it ap-
peared that the former was slightly more effective than the
latter at 5 min and was considerably more effective at 10 min.
This higher efficacy is in accordance with the results ob-
tained for the skin-permeation studies, for which the amount
Figure 6. Evolution of erythema at different times as expressed as relative erythema [%] with respect to the vasodilation stage. Comparison between treat-
ment with 1·brimonidine, MirvasoS, 1·betamethasone, or 1·triamcinolone and their respective controls (no treatment). A comparison between 1·brimoni-
dine and MirvasoS is shown (right). Horizontal bars represent the median value. Statistical significance: *p<0.05, **p<0.01, ***p<0.001, ns=nonsignificant.
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of drug retained inside the skin was almost three times higher
upon applying 1·brimonidine than upon applying MirvasoS.
This shows the effect provided by gel 1·2Br both in facilitating
entry of the drug in the skin and in promoting its retention
within the skin, where it has its therapeutic effect as a vasocon-
strictor and decreases erythema. Also, this retention explains
why 1·brimonidine requires a longer time than MirvasoS to
cross the skin completely (permeation lag time). All of these re-
sults show that gel 1·brimonidine is a promising formulation
for the topical treatment of rosacea.
Likewise, treatment with 1·triamcinolone shows a significant
reduction in erythema after 15 min, also below the basal value
(@53%), and this gel is thus significantly more effective than
the control. In contrast, relative to that observed for the con-
trol, treatment with 1·betamethasone does not show a signifi-
cant reduction in erythema.
Upon considering that erythema can decrease without the
application of any treatment, the efficacy of the different gels
can be estimated more accurately by calculating the decrease
provided by the treatment itself and subtracting the control
value from the treatment value (treatment contribution).
Table 1 shows that the highest treatment contribution is pro-
vided by gel 1·brimonidine (160%), being over six times
higher than that of Mirvaso (25%). Similarly, gel 1·triamcino-
lone decreases erythema very effectively (69%). In contrast,
1·betamethasone shows only a slight increase in erythema.
However, the differences in the efficacies of the treatments
are not only related to permeation parameters such as flux
values or the amount retained within the skin but are also re-
lated to the intrinsic therapeutic activity of the drugs. For in-
stance, in the cases of 1·brimonidine and MirvasoS, the fast ef-
ficacy of both treatments may be due to the mechanism of
action of brimonidine tartrate, which occurs immediately upon
arriving at the a2-adrenergic receptors in the endothelial cells.
In contrast, both 1·triamcinolone and 1·betamethasone incor-
porate glucocorticoid drugs, the mechanism of action of which
is indirect and occurs by regulating the transcription of genes
encoding inflammatory cytokines or adrenergic receptors,
which may be much slower. Even though the skin-permeation
experiments show that the flux and retention within the skin
provided by these gels are higher than those provided by the
commercial formulations, the animal model employed evalu-
ates the efficacy only on the short-term (15 min). Hence, the
lack of activity with 1·betamethasone could be due to this in-
direct, slower mechanism of action, and accurate efficacy
would be more easily observed over a longer term. Despite
this, gel 1·triamcinolone does show a reduction in erythema
15 min after treatment. A possible explanation could be the in-
trinsic pharmacokinetics of this drug, which are faster than
those of betamethasone; that is why triamcinolone is consid-
ered an “intermediate-acting” glucocorticoid, whereas betame-
thasone is considered a “long-acting” glucocorticoid.[24] In any
case, improved efficacy could be observed over a longer term.
3. Conclusions
The supramolecular hydrogels formed upon mixing bis-imida-
zolium amphiphile 1·2Br with water and ethanol were strongly
influenced by both neutral and cationic drugs, whereas previ-
ous work involved studying the incorporation of anionic drugs
and very recently the incorporation of a cationic drug was
studied;[41] these hydrogels were studied for the treatment of
rosacea. The type of drug strongly influenced the nanometric
structure of the gel fibers, and importantly, NMR spectroscopy
indicated that the drugs not only remained dissolved at the in-
terstitial space of the gel (as indicated by SEM) but that up to
0.84 moles of drug per mole of gelator were incorporated
within the fibers. Such incorporation did not seem to be
driven by the charge of the drug, which makes this novel ma-
terial a versatile nanocarrier as a drug-delivery agent. The lack
of a positive coulombic interaction between the gelator host
network and the drug seemed particularly important for effec-
tive release.
Calorimetry showed that the speed of the supramolecular
assembly was highly influenced by the temperature and the
total amount of gel, and assembly was faster at smaller vol-
umes and at 20 8C. Also, the type of drug added influenced
this gelling temperature and speed. The soft structure of the
gel observed in the rheological study showed its suitability for
dermal application. This gel could release more drug than the
commercial formulations available, and it did it with a faster
profile. Upon application to human skin, the gel permitted
faster drug permeation than commercial products. Also, inde-
pendent of the permeation rate, it was very interesting that
a gel based on 1·2Br promoted retention of the drug within
the skin, which is optimum for targeting rosacea and other
skin diseases. This drug retention could also act as a drug
depot and could provide sustained activity for long periods of
time, which would permit an increase in the dosing intervals
and would overcome the problem of missed doses. Further-
more, gels from 1·2Br could be formed at drug concentrations
higher than those of the existing products, which permits
a smaller application of the gel to obtain the same therapeutic
efficacy.
According to the rosacea model developed, the in vivo stud-
ies demonstrated the efficacy of gel 1·triamcinolone 15 min
after treatment and especially that of gel 1·brimonidine after
Table 1. Lag time, relative erythema values, and treatment contribution
after 15 min.
Gel tlag
[a] Relative erythema [%] Treatment
[min] Treatment[b] Control[c] contribution[d] [%]
1·brimonidine 5 @107 53 160
MirvasoS 10 14 39 25
1·triamcinolone 15 @53 16 69
1·betamethasone n.o.[e] 66 49 @17
[a] Time before a significant reduction in erythema was observed (lag
time). [b] Relative erythema 15 min after application of treatment. [c] Rel-
ative erythema without the application of treatment (15 min). [d] Reduc-
tion in erythema provided by the treatment itself after 15 min, consider-
ing the relative erythema of both treatment and control. n.o. : No signifi-
cant reduction in erythema was observed.
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5 min of treatment, and thus, these gels are more efficient
than the commercial product MirvasoS and reduced erythema
even below the basal value.
Finally, the easy and fast preparation of this gel under
simple conditions, that is, room temperature, soft mixing, and
single-dose packing if it is still liquid, makes it a great option
for the industrial-scale production of dermatological formula-




All reagents were of analytical grade. Brimonidine tartrate, betame-
thasone 17-valerate, and triamcinolone acetonide were purchased
from Acofarma (Spain). Phosphate-buffered saline and m-xylene
were purchased from Sigma–Aldrich. Compound 1,3-bis[(3-octa-
decyl-1-imidazolio)methyl]benzene dibromide (1·2Br) was pre-
pared as reported previously.[42]
Methods
Gel Preparation
Gels were always prepared by dissolving gelling compound 1·2Br
in ethanol, adding distilled water as the antisolvent, mixing gently,
and storing without disturbance in closed vials to prevent solvent
evaporation.
Optimization of Gel Formation
Gelling time and overall macroscopic appearance was evaluated as
a function of different factors such as solvent proportion, concen-
tration of gelator, temperature, drug type, and drug concentration.
Influence of Solvent Proportions on Gel Formation
Gel 1·2Br (10 mg) was weighed into different vials. A different
volume of ethanol was added to each vial (0.7, 0.8, 0.9, 1, and
1.1 mL), and the compound was dissolved by sonication. Water
was added to complete a final volume of 2 mL, and samples were
mixed gently with a micropipette. The vials were then left to stand
at room temperature (24 8C) without disturbance. The final concen-
tration of 1·2Br in all gels was 5 mgmL@1, and the final proportions
of ethanol in the gels were 35, 40, 45, 50, and 55%. Gel formation
and stability were confirmed by the titling method and finally by
inverting the vials after 2, 10, and 30 min; 1, 3, and 6 h; 4 days;
and 6 months.
Influence of Concentration of 1·2Br on Gel Formation
Gels of 1·2Br (2 mL) were prepared by weighing different amounts
of 1·2Br (6, 8, 10, 12, 15, and 20 mg) into separate vials. The com-
pound in each vial was dissolved in ethanol (1 mL) with sonication,
after which water (1 mL) was added, and the sample was mixed
gently. The final concentrations of 1·2Br in the gels were 3, 4, 5, 6,
7.5, 8, and 10 mgmL@1. Gel formation and stability were confirmed
as described above.
Influence of Temperature on Gel Formation
Gel 1·2Br (10 mg) was weighed into three different vials. The com-
pound in each vial was dissolved in ethanol (1 mL) with sonication,
and water (1 mL) was added. The mixtures were stirred gently, and
the vials were closed to prevent solvent evaporation. Immediately,
the vials were left to stand at three different temperatures: 5, 24,
and 40 8C. Gel formation and stability were confirmed as described
above.
Influence of Drug Concentration on Gel Formation
The solubilities of the tested drugs were previously determined in
ethanol and water to determine the drug concentrations in the gel
to be assayed. For the gels with 1·2Br and brimonidine tartrate,
the gelator (10 mg) was dissolved in ethanol (1 mL). An aqueous
solution (1 mL) containing different amounts of drug (1, 2.5, 3.5, 5,
10, 20, and 40 mg) was added, and the solution was gently stirred
and left to stand at room temperature. For the gel with 1·2Br and
triamcinolone acetonide or betamethasone 17-valerate, ethanol
(1 mL) containing different amounts of drug (1, 2.5, 5, and 10 mg;
and up to 20 mg in the case of betamethasone 17-valerate) was
added to 1·2Br (10 mg), and the mixture was sonicated until a ho-
mogeneous solution was obtained. Water (1 mL) was added, and
the mixture was gently stirred. The vial was closed to prevent sol-
vent evaporation and was left to stand at room temperature. Gel
formation and stability were confirmed as described above.
Optimum Conditions for Gel Fabrication
Optimum conditions were chosen for the preparation of gels that
were used in the rest of the experiments either with or without
drug, unless stated otherwise. For instance, the final volume was
2 mL with a final concentration of 5 mgmL@1 of 1·2Br as the gela-
tor using 50% ethanol and 50% water with both mixing and stor-
ing at room temperature. The drug concentration was always
5 mgmL@1 so there were no problems for gelling, and this concen-
tration, in all cases, was higher than the concentrations of the
commercially available products, which implied therapeutic doses
would be reached. In the case of the brimonidine tartrate gel
(1·brimonidine), gelator 1·2Br was dissolved in ethanol and was
mixed with the drug dissolved in water. In the cases of the beta-
methasone 17-valerate (1·betamethasone) and triamcinolone ace-
tonide (1·triamcinolone) gels, the drug was dissolved in ethanol,
gelator was dissolved in the same ethanol solution, and water was
added. Samples were mixed gently, closed to prevent solvent
evaporation, and left to stand without disturbance.
Rheological Measurements
For rheological studies, gels with or without drug were formed in
7 cm diameter glass Petri dishes to form a total volume of 27 mL.
Prepared gels were always kept at room temperature overnight
before study. The rheological characterization of each formulation
was performed by using a Haake Rheostress1 rheometer (Thermo
Fisher Scientific, Karlsruhe, Germany) connected to a temperature
controlled Thermo Haake Phoenix II + Haake C25P and equipped
with a parallel plate geometry (Haake PP60 Ti, 60 mm diameter,
3 mm gap between plates).
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Oscillation Amplitude Tests
The amplitude in shear stress t was increased from 0.01 to 100 Pa
with a constant frequency of 1 Hz with the purpose of evaluating
gel strength. Oscillation frequency tests were performed from 0.01
to 10 Hz at a constant shear stress of 0.5 Pa to be within the linear
viscoelastic region to determine the related variation in storage
modulus (G’) and loss modulus (G“) at 32 8C. Both viscoelastic







in which t0 and g0 are the amplitudes of stress and strain, respec-
tively, and d is the phase shift between them. The software Haake
RheoWin Job Manager V.3.3 and RheoWin Data Manager V.3.3
(Thermo Electron Corporation, Karlsruhe, Germany) were used to
perform the test and analysis of the obtained data, respectively.
Drug Incorporation into Gel Fibers
Incorporation of drug into the fibers of gel 1·2Br was quantified
by 1H NMR spectroscopy[8] by using a Varian 400 MHz NMR spec-
trometer from the Centres Cient&fics i Tecnolkgics de la Universitat de
Barcelona (CCiTUB). A total of 32 scans were recorded in every
measurement. Gels from 1·2Br incorporating the drug in a molar
ratio of 1:1 were formed inside the NMR tube, and the drug signals
in the spectra were compared to those from a drug solution at the
same concentration. Aromatic signals from the drug were taken as
the reference signals. To quantify the incorporation of brimonidine
tartrate, two aliquots containing the drug (8.28 mmol, 3.66 mg)
were each dissolved in deuterium oxide (0.75 mL), and the 1H NMR
spectra of both (tubes A and B) were recorded (record 1). After
that, deuterated methanol (0.75 mL) was added to tube A and
1·2Br (7.5 mg, 8.28 mmol) dissolved in deuterated methanol
(0.75 mL) was added to tube B. Both tubes were shaken to pro-
mote mixing, and gel formation in tube B was observed, whereas
tube A remained in solution. The 1H NMR spectra of both tubes
were recorded under the same conditions (record 2). To quantify
incorporation of either betamethasone 17-valerate or triamcino-
lone acetonide, two aliquots containing the drug (8.28 mmol;
3.94 mg of betamethasone 17-valerate, 3.59 mg of triamcinolone
acetonide) were each dissolved in deuterated methanol (0.75 mL),
and the 1H NMR spectra of both (tubes A and B) were recorded
(record 1). After that, 1·2Br (7.5 mg, 8.28 mmol) was dissolved in
tube B with sonication, and deuterium oxide (0.75 mL) was added
to each tube. Both tubes were shaken to promote mixing, and gel
formation was observed in tube B, whereas tube A remained in so-
lution. The 1H NMR spectra of both tubes were recorded under the
same conditions (record 2). The intensities of the drug signals in re-
cords 1 and 2 in the aromatic region were compared to obtain the
amount of drug incorporated inside the gel fibers.
Microscopy
Scanning electron microscopy (SEM) images were acquired by the
Electron Microscopy Service in the Institut de CiHncia de Materials
de Barcelona—Consejo Superior de Investigaciones Cient&ficas
(ICMAB-CSIC) with a QUANTA FEI 200 FEG-ESEM system for samples
deposited on gold on mica from the gel. Contacts were made be-
tween the gold surface and the sample holder with graphite paste
to avoid charging of the unstained xerogels. In all cases, gels were
2 weeks old, and the xerogels were observed after complete evap-
oration of the solvent.
Calorimetric Studies
The gelation of compound 1·2Br was performed in a Microcal VP-
DSC. A mixture (1 mL) of compound 1·2Br with both ethanol and
water was introduced in the equipment at 35 8C. The sample was
then slowly cooled from 35 to 5 8C at a rate of 1 8Cmin@1 to form
a gel inside the equipment while monitoring the specific heat ca-
pacity (Cp) during cooling of the sample. The thermoreversibility
was assayed by performing subsequent heating–cooling cycles.
The experiment was repeated with another sample (0.5 mL) to
assess the influence of the sample volume. Finally, experiments
were performed with gels incorporating either drug (0.5 mL sam-
ples). Data were treated and plotted by using Origin software and
Microsoft Excel software.
Drug-Release Studies
Drug-release studies for the gels were performed in a Microette
transdermal diffusion system (Microette plus-Hanson Research) fol-
lowing a protocol similar to those previously reported.[43, 44] Vertical-
ly assembled Franz-type diffusion cells (Crown Glass) (2.54 cm2 dif-
fusion area) were used. Dialysis membranes (Cellu·Sep T3 dialysis
membrane, MWCO 12000–14000 Da, MFPI, USA), previously hydrat-
ed in ethanol/water (7:3), were placed in the Franz-type diffusion
cells. The receptor chamber contained 10 mm phosphate-buffered
saline (PBS) (pH 7.4) to study gels with brimonidine tartrate and
ethanol/water (7:3) for gels with either betamethasone 17-valerate
or triamcinolone acetonide, all of which complied with SINK condi-
tions.[36] The dialysis membrane and the donor container were put
onto the glass receptor chamber, and the assembly was fixed with
a joint. The Franz-type cells were connected to a controlled tem-
perature circulating bath set to 32 8C. Gels of 1·2Br were prepared
at a drug concentration of 5 mgmL@1. Known weights of gel 1·2Br
with either drug or commercial formulations (&1.6 mg drug) were
placed into the donor compartment onto the dialysis membranes,
and the donor compartment was sealed with plastic paraffin film
to prevent solvent evaporation. Samples were taken at given time
intervals, and every sample taken was replaced by an equal
volume of the receptor solution. Release experiments of gels were
done in triplicate. The concentrations of the samples were deter-
mined by HPLC, and cumulative amounts of released drug as
a function of time were plotted. Kinetic parameters were calculated
from the mean values of three replicas in each type of gel, and
nonlinear least-squares regression was performed by using Graph-
Pad Prism (version 3.00, GraphPad Software, Inc. , USA). Different
models were tested: Higuchi’s square root of time, Korsmeyer–
Peppas, One-Phase Exponential Assosiation (first-order), Weibull’s
equation, and zero order. The best model was chosen according to
the R2 value obtained.
Skin-Permeation Studies
The permeation assay was done with human skin from the ab-
dominal region obtained during plastic surgery of a healthy,
40 year-old woman who gave written, informed consent for the
use of this material for research purposes. The protocol was similar
to that followed in the drug-release study, replacing the dialysis
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membranes with skin previously dermatomed at 0.4 mm thickness
and placed with the stratum corneum facing the donor compart-
ment, according to guidelines.[45, 46] Skin was used for every differ-
ent formulation (n=5). The temperature was adjusted to 32 8C, the
normal skin temperature in humans, and experiments were per-
formed for only 27 h to prevent damage of the biological material.
The receptor medium was always elected to comply with SINK
conditions to discard the possibility that a slow permeation profile
would be limited by the low solubility of the drug in the receptor
medium.[36] For instance, 10 mm PBS buffer pH 7.4 was used for the
skin permeation of brimonidine tartrate, and a mixture of ethanol/
water (7:3) was used for the permeation of triamcinolone aceto-
nide and betamethasone 17-valerate. Available marketed formula-
tions containing brimonidine tartrate (MirvasoS), triamcinolone
acetonide (PositonS), or betamethasone 17-valerate (CelecremS)
were also studied for comparison purposes. Moreover, to assess
the influence of the gel material itself and to discard other factors
such as different concentrations of the drug, brimonidine tartrate
was taken as a model and was also incorporated in gel 1·2Br at
the same concentration as the commercial product MirvasoS
(3.3 mgmL@1). The gel was applied on the donor compartment in
contact with the epidermal side of the skin (&1.6 mg drug). The
samples were taken at given time intervals for 24 h. Concentrations
were determined by using HPLC, and cumulative amounts of drug
permeated were plotted. Kinetic parameters were calculated from
the median and range values by performing a linear least-squares
regression in the linear zone of the plot[47] by using GraphPad
Prism (version 3.00, GraphPad Software, Inc. , USA).
Drug Retention on Skin
At the end of the permeation study, the amount of retained drug
inside the skin was evaluated.
Drug Extracted from the Skin
At the end of the permeation study, retained drug inside the skin
was evaluated by following a protocol described elsewhere.[43] The
skin was removed from the Franz cell, cleaned with gauze soaked
in a 0.05% solution of sodium dodecyl sulfate, and washed in dis-
tilled water accurately. The permeation area of the skin was then
excised, punctured with a needle, and weighed, and the drug con-
tained therein was extracted with the corresponding receptor
medium (1 mL) during 20 min of sonication. The resulting solutions
were measured by HPLC, which yielded the amount of drug ex-
tracted from the skin expressed in mgg@1cm@2.
Drug-Recovery Experiments
Drug solutions at known concentrations were prepared by using
the receptor medium used in the release and skin-permeation
studies as the solvent. For instance, concentrations were
133 mgmL@1 for brimonidine tartrate and 5000 mgmL@1 for both tri-
amcinolone acetonide and betamethasone 17-valerate. An aliquot
(1 mL) of each drug was taken, and pieces of skin from the same
patient as in the permeation experiments were immersed in each
drug solution and kept at 32 8C for 27 h. The skin pieces were
cleaned with gauze soaked in a 0.05% solution of sodium dodecyl
sulfate and were washed in distilled water accurately. Drug concen-
trations of both solutions “before immersion” and “after immer-
sion” were determined by using HPLC to know the amount of
drug that could be retained within the skin. Skin pieces were punc-
tured with a needle, and drug was extracted with the correspond-
ing receptor solution (1 mL) by using sonication, as performed in
the drug-retention experiments. Concentrations of the drug extrac-
tions were determined by using HPLC. The percentage of drug
that could be recovered after being retained within skin was deter-
mined as follows [Eq. (3)]:
Drug recovery ½%A ¼ ðdrug extracted ½mgAÞðdrug retained ½mgAÞ ð3Þ
Drug Retention Inside the Skin
The percentage of drug recovery was used to estimate the real
amount of drug retained within skin during the skin-permeation
experiments. Nonparametric Mann Whitney test statistical analyses
were performed to compare the drug retention values from differ-
ent formulations.[47]
HPLC Determination
Concentrations of brimonidine tartrate in the samples were ob-
tained by HPLC with a Waters LC Module I by using a Waters
Spherisorb 5 mm ODS-2 (4.6 mmV150 mm) column. Concentrations
of triamcinolone acetonide and betamethasone 17-valerate in the
samples were obtained by using an HPLC with a Waters 717 plus
autosampler and a 600 controller pump equipped with a 2996
photodiode array detector by using a 4 mm (3.9 mmV150) Nova-
Pack C18 column. To quantify brimonidine tartrate, the mobile
phase consisted of acetonitrile/water (50:50, acidified to pH 2.4
with acetic acid) with a flow rate of 1 mLmin@1 setting a detection
wavelength of 316 nm. To quantify betamethasone 17-valerate, the
mobile phase consisted of acetonitrile/water following a gradient
that consisted of 35:65 at t=0 min, 100:0 at t=10 min, 35:65 at
t=11 min, and 35:65 at t=16 min with a flow rate of 1 mLmin@1.
The detection wavelength was set to 239 nm. Each sample had
a run time of 16 min. To quantify triamcinolone acetonide, the
mobile phase consisted of acetonitrile/water following a gradient
that consisted of 40:60 at t=0 min, 85:15 at t=8 min, 40:60 at t=
9 min, and 40:60 at t=14 min with a flow rate of 1 mLmin@1. The
detection wavelength was set to 239 nm. Each sample had a run
time of 14 min. The data were collected by using Millennium32
version 4.0.0 software from Waters Corporation.
Pharmacological Efficacy In Vivo
All experiments were performed in compliance with the Universitat
de Barcelona Committee of Ethics at the Animal Experimentation
Unit of Hospital de Bellvitge. The pharmacological efficacies of gels
1·brimonidine, MirvasoS, 1·triamcinolone, and 1·betamethasone
were tested in four groups of rabbits, each group corresponding
to one kind of gel (n=4). Gel 1·brimonidine was used at a drug
concentration of 3.3 mgmL@1, the same as that of Mirvaso, for
comparison purposes. Gels 1·triamcinolone and 1·betamethasone
were used at a drug concentration of 5 mgmL@1. The skin color of
the rabbit was determined in both ears by using a MPA5 Multip-
robe adapter from Courage+Khazaka electronic GmbH, equipped
with a CL400 skin colorimeter probe from Courage+Khazaka elec-
tronic GmbH, Germany. The device emitted a white LED light that
homogeneously illuminated a circular part of the skin. The light
scattered by the skin was detected by the colorimeter probe, and
it is expressed as the intensity of light of the three basic light com-
ponents, R, G, and B (red, green, and blue), on the scale of 0 to
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255 each. After measuring the basal skin color, vasodilation and er-
ythema were induced in both ears by applying m-xylene in a limit-
ed region of the dorsal side of the ears with the help of sterile
gauze, and the skin color of both ears was determined again. Im-
mediately after, an aliquot (400 mL) of 1·brimonidine, MirvasoS,
1·triamcinolone, or 1·betamethasone was applied to the limited
region in the right ear as treatment, leaving the left ear without
treatment as control. Skin color determinations were performed
after 5, 10, and 15 min of treatment. Pictures of the rabbit ears
from the first rabbit of each group were taken immediately before
each color measurement. Colors were reproduced by using Micro-
soft Excel software from the RGB codes and were plotted as a se-
quence. To determine the difference between the colors, RGB
codes were treated as xyz Cartesian coordinates in the Euclidean
space, (red as x, green as y, and blue as z) and were plotted in
a 3D scatter plot. For any pair of colors A (R1, G1, B1) and B (R2, G2,
B2), the difference was obtained first by calculating the linear dis-
tance in the space between these two points and then by assess-
ing the sense of the distance. The linear distance was obtained by
using the analytical geometry equation [Eq. (4)]:
!
AB
444 444 ¼ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃðR2 @ R1Þ2 þ ðG2 @ G1Þ2 þ ðB2 @ B1Þ2q ð4Þ
The linear distance does not permit determination of whether
a color is darker or lighter than the other, but only how different it
is. Therefore, the sense of the distance was obtained by calculating
the overall difference in light intensity [Eq. (5)]:
Dintensity ¼ ðR2 @ R1Þ þ ðG2 @ G1Þ þ ðB2 @ B1Þ ð5Þ
For this equation, a negative result corresponds to a darker color,
which was the case of erythema and to which a sense value of (+
1) was assigned, and a positive result corresponds to a lighter
color, which implies less erythema and to which a sense value of
(@1) was assigned. Finally, the difference between the two colors
was obtained by multiplying the linear distance by the sense of
the distance. Differences were calculated between the basal
median value and each measurement. The difference obtained be-
tween the basal color and the one after inducing vasodilation (vas-
odilation difference) was considered 100% erythema. Hence, rela-
tive erythema [%] values were calculated with respect to the vaso-
dilation difference and were plotted as a sequence of the different
stages to see the evolution of erythema. One-way analysis of var-
iance (ANOVA) with Tukey’s multiple comparison tests was per-
formed to assess the statistical significance of both the evolution
of erythema and the comparison between treatment and control.
Nonparametric Kruskal–Wallis tests were performed to assess the
statistical significance of the comparison between different treat-
ments (1·brimonidine vs. MirvasoS). All statistical analyses were
performed by using GraphPad Prism software version 3.0.
Acknowledgements
This work was supported by EU ERDF (FEDER) funds and the
Spanish Government grant TEC2014-51940-C2-2-R. Dr. Lyda Hal-
baut from Universitat de Barcelona is acknowledged for her help
with rheology studies. D.L. thanks CONACYT for a predoctoral
grant.
Conflict of Interest
The authors declare no conflict of interest.
Keywords: drug delivery · hydrogels · skin permeation ·
supramolecular chemistry · surfactants
[1] M. P. Lutolf, Nat. Mater. 2009, 8, 451.
[2] N. M. Sangeetha, U. Maitra, Chem. Soc. Rev. 2005, 34, 821.
[3] K. J. Skilling, F. Citossi, T. D. Bradshaw, M. Ashford, B. Kellam, M. Marlow,
Soft Matter 2014, 10, 237.
[4] L. Meazza, J. A. Foster, K. Fucke, P. Metrangolo, G. Resnati, J. W. Steed,
Nat. Chem. 2013, 5, 42.
[5] M. De Loos, B. L. Feringa, J. H. Van Esch, Eur. J. Org. Chem. 2005, 3615.
[6] N. J. Manesis, A. Back, US Patent 2014020028681, 2013.
[7] M. Rodrigues, A. C. Calpena, D. B. Amabilino, M. L. GarduÇo-Ram&rez, L.
P8rez-Garc&a, J. Mater. Chem. B 2014, 2, 5419.
[8] D. Limjn, E. Amirthalingam, M. Rodrigues, L. Halbaut, B. Andrade, M. L.
GarduÇo-Ram&rez, D. B. Amabilino, L. P8rez-Garc&a, A. C. Calpena, Eur. J.
Pharm. Biopharm. 2015, 96, 421.
[9] K. J. Skilling, A. Ndungu, B. Kellam, M. Ashford, T. D. Bradshaw, M.
Marlow, J. Mater. Chem. B 2014, 2, 8412.
[10] European Medicines Agency, Mirvaso: EPAR—Public assessment report
2013, pp. 1–107.
[11] W. H. Binder, L. Petraru, T. Roth, P. W. Groh, V. P#lfi, S. Keki, B. Ivan, Adv.
Funct. Mater. 2007, 17, 1317.
[12] Z. Yang, G. Liang, B. Xu, Acc. Chem. Res. 2008, 41, 315.
[13] H. Wang, Z. Luo, Y. Wang, T. He, C. Yang, C. Ren, L. Ma, C. Gong, X. Li, Z.
Yang, Adv. Funct. Mater. 2016, 26, 1822.
[14] K. Hayashi, W. Sakamoto, T. Yogo, Adv. Funct. Mater. 2016, 26, 1852.
[15] H. Maeda, Chem. Eur. J. 2008, 14, 11274.
[16] X. Yao, X. Wang, T. Jiang, X. Ma, H. Tian, Langmuir 2015, 31, 13647.
[17] C. Rizzo, F. D’Anna, R. Noto, M. Zhang, R. G. Weiss, Chem. Eur. J. 2016,
22, 11269.
[18] L. Casal-Dujat, P. C. Griffiths, C. Rodr&guez-Abreu, C. Solans, S. Rogers, L.
P8rez-Garc&a, J. Mater. Chem. B 2013, 1, 4963.
[19] E. Amirthalingam, M. Rodrigues, L. Casal-Dujat, A. C. Calpena, D. B. Ama-
bilino, D. Ramos-Ljpez, L. P8rez-Garc&a, J. Colloid Interface Sci. 2015,
437, 132.
[20] M. Rodrigues, A. C. Calpena, D. B. Amabilino, D. Ramos-Ljpez, J. de La-
puente, L. P8rez-Garc&a, RSC Adv. 2014, 4, 9279.
[21] K. Yamasaki, A. Di Nardo, A. Bardan, M. Murakami, T. Ohtake, A. Coda,
R. A. Dorschner, C. Bonnart, P. Descargues, A. Hovnanian, V. B. Morhenn,
R. L. Gallo, Nat. Med. 2007, 13, 975.
[22] G. H. Crawford, M. T. Pelle, W. D. James, J. Am. Acad. Dermatol. 2004, 51,
327.
[23] V. H. van der Velden, Mediators Inflammation 1998, 7, 229.
[24] G. Chrousos, A. N. Pavlaki, M. A. Magiakou, Glucocorticoid Therapy and
Adrenal Suppression ; MDText.com, Inc. , 2011.
[25] Spanish Agency of Medicinal Products, Online Medicines Information
Center—AEMPS—CIMA, 1994.
[26] Spanish Agency of Medicinal Products, Technical Specifications of the
Drug, 2014.
[27] Spanish Agency of Medicinal Products, Online Medicines Information
Center—AEMPS—CIMA, 1999.
[28] A. Vintiloiu, J.-C. Leroux, J. Controlled Release 2008, 125, 179.
[29] M. A. Rogers, J. H. J. Kim, Food Res. Int. 2011, 44, 1447.
[30] Y. Hashimoto, S. Mukai, S. Sawada, Y. Sasaki, K. Akiyoshi, Biomaterials
2015, 37, 107.
[31] J. Carvalho, S. Moreira, J. Maia, F. M. Gama, J. Biomed. Mater. Res. Part A
2010, 93A, 389.
[32] A. I. Van Den Bulcke, B. Bogdanov, N. De Rooze, E. H. Schacht, M. Corne-
lissen, H. Berghmans, Biomacromolecules 2000, 1, 31.
[33] V. Breedveld, A. P. Nowak, J. Sato, T. J. Deming, D. J. Pine, Macromole-
cules 2004, 37, 3943.
[34] N. J. Babu, A. Nangia, Cryst. Growth Des. 2011, 11, 2662.
[35] T. Xie, L. S. Taylor, Mol. Pharm. 2016, 13, 873–884.
[36] M. Gibaldi, S. Feldman, J. Pharm. Sci. 1967, 56, 1238.
[37] J. A. Cramer, R. H. Mattson, M. L. Prevey, R. D. Scheyer, V. L. Ouellette,
JAMA J. Am. Med. Assoc. 1989, 261, 3273.
[38] M. D. Nettleman, M. J. Bock, Clin. Perform. Qual. Health Care 1996, 4,
148.
ChemistryOpen 2017, 6, 585 – 598 www.chemistryopen.org T 2017 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim597
[39] R. Koczulla, G. Von Degenfeld, C. Kupatt, F. Krçtz, S. Zahler, T. Gloe, K.
Issbrecker, P. Unterberger, M. Zaiou, C. Lebherz, A. Karl, P. Raake, A.
Pfosser, P. Boekstegers, U. Welsch, P. S. Hiemstra, C. Vogelmeier, R. L.
Gallo, M. Clauss, R. Bals, J. Clin. Invest. 2003, 111, 1665.
[40] J. Q. Del Rosso, J. Am. Acad. Dermatol. 2013, 69, S44.
[41] D. Limjn, C. Jim8nez-Newman, A. C. Calpena, A. Gonz#lez-Campo, D. B.
Amabilino, L. P8rez-Garc&a, Chem. Commun. 2017, 53, 4509.
[42] L. Casal-Dujat, M. Rodrigues, A. Yagee, A. C. Calpena, D. B. Amabilino, J.
Gonz#lez-Linares, M. Borr/s, L. P8rez-Garc&a, Langmuir 2012, 28, 2368.
[43] E. Gonz#lez-Mira, S. Nikolic´, M. L. Garc&a, M. A. Egea, E. B. Souto, A. C.
Calpena, J. Pharm. Sci. 2011, 100, 242.
[44] G. Abrego, H. Alvarado, E. B. Souto, B. Guevara, L. H. Bellowa, A. Parra,
A. Calpena, M. L. Garcia, Eur. J. Pharm. Biopharm. 2015, 95, 261.
[45] Scientific Committee on Consumer Safety, Eur. Comm. 2010, SCCS/1358,
1.
[46] OECD, Guidelines for the Testing of Chemicals, Section 4, Test No. 428:
Skin Absorption: In Vitro Method, 2004.
[47] A. C. Williams, P. A. Cornwell, B. W. Barry, Int. J. Pharm. 1992, 86, 69.
Received: February 27, 2017
Version of record online July 17, 2017
ChemistryOpen 2017, 6, 585 – 598 www.chemistryopen.org T 2017 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim598
